Technology

Histogenics Says Phase 3 Trial of NeoCart Failed to Meet Primary Endpoint

Histogenics Says Phase 3 Trial of NeoCart Failed to Meet Primary Endpoint

Shares of Histogenics (HSGX), a clinical-stage company focused on the development of restorative cell therapies, fell nearly 64% in pre-market trading Wednesday after the company said its phase 3 trial of NeoCart failed to meet the primary endpoint of a statistically significant improvement in pain and function in a dual threshold responder analysis one year after treatment as compared to […]

bluebird bio Says Phase 2/3 Starbeam Study Meets Enrollment Goal

bluebird bio Says Phase 2/3 Starbeam Study Meets Enrollment Goal

bluebird bio (BLUE) reported Wednesday that its phase 2/3 Starbeam study of its investigational Lenti-D gene therapy in boys 17 years of age and under with cerebral adrenoleukodystrophy (CALD), has met its enrollment goal; it also reported initial data from ALD-103, the ongoing observational study of outcomes from allogeneic hematopoietic stem cell transplant (allo-HSCT) in boys 17 years of age […]

Workday Ramps up Full Year Outlook After Second Quarter Results Top Street View

Workday Ramps up Full Year Outlook After Second Quarter Results Top Street View

Cloud computing company Workday (WDAY) raised its full year revenue outlook late on Tuesday as it posted better-than-expected results for its top and bottom lines which was buttressed by a jump in subscriptions. The Pleasanton, California-headquartered company, which provides enterprise cloud applications for financial management and human capital management, generated total revenue of $671.7 million in the quarter ended July […]

Helios and Matheson Crumbles To Record Low on Q2 Loss

Shares of Helios and Matheson Analytics (HMNY), the parent company of MoviePass, fell to a new all-time low of $0.03 in early Wednesday trading following the release of disappointing Q2 results in which the company said it has “substantial doubt” it can continue as a going concern. “Without raising additional capital, there is substantial doubt about the Company’s ability to […]

Musk’s Tweet on Taking Tesla Private May Indicate He Has `Significant’ Funding Lined Up

Musk’s Tweet on Taking Tesla Private May Indicate He Has `Significant’ Funding Lined Up

Tesla (TSLA) Chief Executive Elon Musk tweeted on Tuesday that he is considering taking the company private at $420 a share, a 22% premium to its closing price the day before, and given his demeanor it seems there may be “significant” funding already lined up, RBC Capital Markets said in a note to clients. “Elon’s tone and messaging regarding a […]

Discovery Communications Misses Views on Adjusted Earnings

Discovery Communications Misses Views on Adjusted Earnings

Discovery Communications (DISCA) released disappointing quarterly results on Tuesday that sent its stock price into the red, with the broadcaster reporting “tepid underlying growth trends,” according to Pivotal Research. Adjusted earnings per diluted share slipped to $0.66 from $0.68, missing the consensus on Capital IQ for $0.86 a share. Revenue jumped 63% to $2.85 billion, in line with the Street’s […]

Tesla Stock Surges as Musk Says May Take Company Private

Tesla Stock Surges as Musk Says May Take Company Private

Tesla (TSLA) shares jumped on Tuesday after co-founder Elon Musk tweeted that he was considering taking the electric-vehicle maker private. “Am considering taking Tesla private at $420. Funding secured,” the company’s chief executive officer said from his Twitter account. The shares were recently trading at $360.99. Musk, who often engages with both supporters and detractors on social media, didn’t offer […]

Neovasc Soars 17% as Data Showed Neovasc Reducer ‘Very Safe’ in Significantly Lowering Angina Severity

Neovasc Soars 17% as Data Showed Neovasc Reducer ‘Very Safe’ in Significantly Lowering Angina Severity

Shares of Neovasc (NVCN), a developer of minimally invasive transcatheter mitral valve replacement technologies, surged 17% intraday after the company said Monday results from a study undertaken to assess the safety and effectiveness of the Neovasc Reducer showed that the treatment was “very safe and significantly reduced the severity of angina.” In the published study, the safety and effectiveness of […]